4C-I, also known chemically as 4-Iodo-2,5-dimethoxyphenethylamine, is a synthetic psychedelic compound in the phenethylamine class. It is structurally related to mescaline and 2C-I but contains an iodine atom at the fourth position, which contributes to its unique pharmacological and psychoactive profile. 4C-I primarily acts as a serotonergic psychedelic, influencing the brain’s serotonin system to alter perception, emotion, and cognition.

• Serotonin Receptor Agonist: 4C-I primarily binds to the 5-HT2A receptor in the brain, which is the same receptor targeted by most classic psychedelics. This binding alters normal serotonin signaling and induces visual, sensory, and emotional changes.

• Phenethylamine Structure: It belongs to the phenethylamine family, a group of compounds known for producing stimulation and altered consciousness. The iodine substitution gives it different binding affinities compared to other similar molecules like 2C-I.

• Consciousness-Expanding Effects: Users report enhanced introspection, changes in thought patterns, heightened emotions, and philosophical or spiritual insights during the experience.

• Visual and Sensory Distortions: At effective doses, 4C-I is known to induce vibrant visual distortions, light trails, enhanced colors, and auditory changes without completely detaching from reality.

• Mild to Moderate Stimulation: It produces subtle physical energy without the jitteriness of classic stimulants. This allows users to remain mobile and engaged during the experience.

• Dose-Dependent Intensity: Lower doses typically offer enhanced mood and visual perception, while higher doses may lead to ego softening, temporal distortion, and more profound altered states.

The legal status of 4C-I varies significantly around the world and is often complex due to its classification as a research chemical. While it may not be explicitly scheduled in some jurisdictions, it could still fall under analogue or blanket bans depending on local laws. Users and buyers are responsible for ensuring compliance with their country’s legal framework before purchasing or using 4C-I.

• United States (Federal Level): 4C-I is not scheduled under the Controlled Substances Act, but it could be considered an analogue of 2C-I, which is a Schedule I drug. The Federal Analogue Act may apply if intended for human consumption.

• Europe: Countries like the United Kingdom, Germany, and Sweden have banned 4C-I under psychoactive substance regulations or as part of blanket bans on substituted phenethylamines.

• Canada and Australia: These countries have broad scheduling laws where 4C-I may fall under analogue or structural derivative rules. However, enforcement and legal clarity can vary by province or state.

• Research Use Exceptions: In some regions, 4C-I can be legally possessed for academic or scientific research purposes, provided it is not marketed for human consumption.

• Customs Risks: Even if legal in your country, importing 4C-I may be flagged by customs if it resembles a controlled substance. Discreet packaging, as offered by Psycho Plug, helps mitigate this risk.

• Legal Responsibility of Buyer: We ship to most countries, but the customer is responsible for verifying their local laws and regulations before ordering.

4C-I produces a blend of visual, cognitive, and emotional effects that are characteristic of psychedelic substances, but with its own distinct profile. The experience tends to be less overwhelming than that of LSD or DMT, making it suitable for users seeking both introspection and sensory enhancement without full ego dissolution.

• Enhanced Visual Perception: Users frequently report vibrant, shifting color patterns, enhanced contrast, motion trails, and geometric visuals, particularly in dim lighting or closed-eye settings.

• Emotional Depth: The compound tends to induce emotional introspection, allowing users to confront suppressed feelings or achieve emotional clarity. It may produce feelings of empathy, compassion, or sadness depending on set and setting.

• Altered Cognition: Thought processes become non-linear, more abstract, and philosophical. This is often described as “zooming out” from habitual thinking to gain higher-level perspective.

• Time Distortion: Time may appear to slow down or speed up, with users reporting that a few minutes can feel like hours during peak effects.

• Spiritual and Mystical Experiences: Some users describe sensations of oneness, ego softening, or communion with nature or the universe, especially at higher doses.

• Increased Sensory Awareness: Sounds may feel richer or more layered, and tactile sensations may be heightened, leading to synesthesia-like experiences for sensitive individuals.

• Afterglow Effect: Following the primary effects, many users report a pleasant emotional afterglow—feeling grounded, reflective, and emotionally open for several hours or even days.

Dosing 4C-I requires precision and patience due to its potency and long duration. Accurate weighing and careful planning are essential to avoid unpleasant effects or overdose. First-time users should always start with a lower dose to assess personal sensitivity.

• Threshold Dose (5–10 mg): At this level, subtle shifts in perception, mood enhancement, and light visual effects may occur without full psychedelic intensity.

• Light Dose (10–15 mg): Offers moderate visual enhancement, slight time distortion, and emotional insight, suitable for cautious beginners in a safe environment.

• Common Recreational Dose (15–25 mg): Produces strong visuals, mental shifts, and emotional depth. This is the typical range for most users seeking a full experience.

• High Dose (25–35 mg): Reserved for experienced users. Can lead to ego softening, deep philosophical insight, and overwhelming sensory input. Not recommended without a trip-sitter.

• Avoid Eyeballing Doses: Always use a precise digital milligram scale. Visual estimation of powder is dangerous and can easily lead to overdose.

• Oral Ingestion Preferred: Capsules or sublingual application are the safest and most consistent methods. Insufflation or injection is not recommended and may be unsafe.

• Hydration and Environment: Always stay hydrated and choose a calm, familiar environment. Have a sober guide nearby if trying a new or higher dose.

4C-I is a long-lasting psychedelic that unfolds gradually and maintains its effects for several hours. Users should set aside an entire day when planning a session, especially when taking moderate to high doses. The compound offers a slow come-up and an extended plateau, which can be ideal for introspection or prolonged creative tasks.

• Onset Time: Effects typically begin within 45–90 minutes of oral ingestion. The slow onset allows users to prepare mentally and physically as the experience unfolds.

• Time to Peak: Peak effects usually occur 2 to 4 hours after ingestion, featuring the most intense visuals, emotional resonance, and altered cognition.

• Total Duration: The full experience usually lasts between 8 to 12 hours depending on dosage, metabolism, and environmental factors. Higher doses may push this toward the longer end.

• Afterglow Duration: After the peak subsides, users often experience a mellow, contemplative phase that can last 2–4 hours. This is a good time for integration, journaling, or quiet reflection.

• Return to Baseline: Most users report feeling completely back to baseline by the 12 to 14-hour mark, though a lingering sense of mental openness may persist.

• Sleep Considerations: Due to its stimulating nature, sleep may be difficult if taken late in the day. Many users recommend starting early in the morning to avoid sleep disruption.

4C-I is typically available in powder or crystalline form, both of which are designed for accurate dosing and long-term storage. These forms are ideal for research and exploration purposes, offering versatility and ease of use. At Psycho Plug, we offer only lab-tested 4C-I in secure, contamination-free packaging to preserve integrity and effectiveness during transit and storage.

• Powder Form: The most common and versatile form of 4C-I. Fine, consistent powder allows precise weighing and is suitable for oral encapsulation or dissolution in solution.

• Crystalline Form: Appears as small, glistening, off-white crystals. This form is stable, easy to store, and less likely to clump or degrade over time under proper conditions.

• Vacuum-Sealed Packaging: Each order is sealed in a tamper-evident, air-tight vacuum pouch to protect against moisture, oxidation, and contamination during shipping.

• Pre-Weighed Options: We offer various weight quantities to suit different research or storage needs, ensuring both small-scale and bulk buyers can find a suitable size.

• Stability Under Storage: Both powder and crystals remain chemically stable for months if stored in a cool, dry place. Our packaging includes desiccants to maintain dryness.

• Neutral Appearance: The physical appearance of 4C-I (white to off-white) is typical for high-purity phenethylamines and indicates clean synthesis and purification processes.

• No Additives or Fillers: We provide 100% pure product—free from binders, dyes, or carrier agents—to maintain research-grade quality.

Combining 4C-I with other substances, whether recreational or therapeutic, significantly increases complexity and potential risks. As a potent serotonergic psychedelic, 4C-I interacts with the brain’s neurochemical systems in powerful ways. Mixing it with other compounds—especially without thorough knowledge—can lead to unpredictable effects or even medical emergencies.

• Avoid Combining with Stimulants: Substances like amphetamines or MDMA can dangerously increase heart rate, blood pressure, and anxiety when combined with 4C-I, raising the risk of serotonin syndrome or cardiovascular complications.

• Benzodiazepines for Emergency Use Only: While benzos can reduce anxiety or “trip anxiety” in emergencies, they may also blunt the therapeutic or introspective aspects of the experience. They should not be used preemptively or casually.

• Cannabis Amplifies Effects: Many users find that cannabis intensifies visuals and emotional sensitivity during a 4C-I trip, though it can also induce confusion or paranoia if not used carefully.

• Avoid MAOIs at All Costs: Monoamine oxidase inhibitors interfere with the body’s ability to process serotonin. Combining these with 4C-I can lead to severe, life-threatening serotonin toxicity.

• Alcohol and Depressants Not Recommended: These substances dull the clarity and depth of the psychedelic experience and may increase nausea or impair coordination and judgment.

• Synergistic Risk with Other Psychedelics: Mixing 4C-I with LSD, psilocybin, or DMT may result in cognitive overload, unpredictable visuals, and extreme psychological effects. Such combinations should only be attempted by experienced users under controlled conditions.

• Always Research Interactions Thoroughly: If you are considering a combination for experimental purposes, consult peer-reviewed literature and harm-reduction resources. When in doubt, abstain.

4C-I can be suitable for first-time psychedelic users, but only under the right conditions. While it is generally considered less overwhelming than compounds like LSD or DMT, its long duration and introspective intensity still require thoughtful preparation. First-time users should prioritize safety, environment, and support to ensure a manageable and meaningful experience.

• Start with Low Dosage: Beginners should not exceed 10–15 mg on their first experience. This range offers a glimpse into 4C-I’s effects without the risk of intense disorientation.

• Have a Trip-Sitter Present: A sober and trusted companion can provide reassurance, help navigate challenging thoughts, and respond to any unexpected issues.

• Set and Setting Matter: Choose a quiet, comfortable, and familiar location. Avoid crowded or unfamiliar spaces that may cause anxiety or sensory overload.

• Expect Emotional Depth: Even at low doses, 4C-I may bring buried emotions or suppressed memories to the surface. Be mentally prepared for vulnerability and reflection.

• Plan for a Full Day: With an 8–12 hour duration, the experience will take up most of the day. Clear your schedule and avoid planning other activities immediately afterward.

• Avoid Poly-Substance Use: First-time users should not combine 4C-I with other drugs, including alcohol or cannabis. Simplicity ensures safety and clarity.

• Post-Trip Integration: Journaling or discussing the experience afterward helps process insights and integrate them into daily life. This step is especially valuable for first-time users.

Proper storage of 4C-I is crucial to preserving its potency, purity, and chemical stability over time. Being a delicate organic compound, 4C-I is susceptible to degradation if exposed to heat, light, or moisture. By storing it correctly, users and researchers can ensure the substance remains effective for months or even years.

• Cool, Dry, and Dark Environment: Store 4C-I in a place that is free from humidity and direct sunlight. Closets, cabinets, or drawers that maintain room temperature work well if the compound is sealed properly.

• Use Airtight Containers: Re-sealable glass jars or heavy-duty plastic containers with tight seals prevent air and moisture from entering and degrading the compound.

• Vacuum-Sealed or Foil Bags: We ship our 4C-I in vacuum-sealed pouches to protect it during transit. Keeping the product in these bags adds extra protection against environmental damage.

• Include Desiccants: Silica gel packs or other moisture-absorbing agents can be placed in the container to control internal humidity and prevent clumping or breakdown.

• Refrigeration Option: For long-term storage (6 months or more), refrigerating the sealed container extends shelf life. Make sure the product is in a waterproof barrier to avoid condensation.

• Avoid Frequent Opening: Repeatedly opening the container exposes the compound to air and moisture. If frequent access is needed, split the product into smaller single-use portions.

• Label Clearly: Mark the container with the product name, date of purchase, and dosage information to ensure safe and organized storage, especially if you have multiple research compounds.

There is no scientific evidence suggesting that 4C-I causes physical dependence or withdrawal symptoms, and it does not interact with the brain’s dopamine system in the way that addictive drugs do. However, as with many psychedelics, psychological patterns of repeated use can develop, especially in those seeking emotional escape or novelty. Responsible use is essential.

• No Physical Dependence: 4C-I does not produce cravings, physical withdrawal, or compulsive redosing. Users can stop using it without physical discomfort.

• Rapid Tolerance Build-Up: After one use, tolerance develops quickly. This makes repeated use ineffective within a short period and discourages daily or frequent consumption.

• Psychological Attachment Possible: While not physically addictive, users may become mentally reliant on the emotional release or escapism offered by psychedelic experiences.

• Does Not Activate Reward Pathways: Unlike opioids or stimulants, 4C-I does not engage the dopaminergic reward circuitry associated with drug addiction.

• Encourages Spacing Between Sessions: Most experienced users naturally take breaks of several weeks or months between sessions to allow for reflection and reset tolerance.

• No Documented Abuse Patterns: There are currently no major case studies or medical reports suggesting chronic misuse or long-term abuse of 4C-I.

• Safer Use Through Intention: Setting clear intentions before each session helps ensure responsible and therapeutic use rather than indulgent or escapist behavior.

4C-I and 2C-I are both synthetic psychedelics from the phenethylamine class, but they differ in structure, duration, intensity, and subjective experience. These differences make each compound uniquely suited for specific research or experiential purposes. Understanding their distinctions helps users choose the right compound for their goals.

• Structural Difference: While both compounds share a dimethoxyphenethylamine base, 4C-I has a longer carbon chain (butyl group) compared to 2C-I’s ethyl group, which contributes to its slower onset and extended duration.

• Duration of Effects: 4C-I lasts significantly longer than 2C-I, with a typical experience ranging from 8–12 hours, whereas 2C-I usually lasts about 6–8 hours. This makes 4C-I better suited for in-depth exploration but less ideal for short experiences.

• Subjective Intensity: 2C-I is generally described as more energetic and euphoric, with a social and recreational quality. In contrast, 4C-I leans toward introspective and meditative states, making it more aligned with self-exploration and therapeutic use.

• Visual Effects: 4C-I often produces slower, more fluid visual distortions with a dream-like quality. 2C-I visuals tend to be brighter, more geometric, and reactive to light and movement.

• Emotional Tone: Many users report that 4C-I carries a gentler, more emotionally grounded tone, while 2C-I may feel more stimulating and emotionally shallow at similar doses.

• Body Load: 2C-I can sometimes produce a harsher body load (e.g., nausea, tension), while 4C-I is typically considered smoother on the body, especially at moderate doses.

• Use Context: 2C-I is favored for light recreational environments and social gatherings, while 4C-I is better suited for quiet, introspective settings or therapeutic frameworks.

4C-I is not approved for human consumption and is sold strictly for research or analytical purposes. However, based on anecdotal user reports and structural similarities to related compounds, it appears to carry a relatively low physical toxicity profile when used responsibly. Still, lack of clinical research and regulatory approval means its safety cannot be guaranteed.

• Research Chemical Status: 4C-I has not undergone large-scale human trials for safety or toxicity. It is classified as a research compound, meaning all effects are based on anecdotal or uncontrolled case reports.

• No Documented Fatalities: To date, there are no known cases of death directly attributed to responsible 4C-I use. However, due to its psychoactive nature, mental or physical complications are possible under poor conditions.

• Physical Risks: Common physical side effects include pupil dilation, increased heart rate, mild nausea, and muscle tension. These are usually temporary but can be problematic in users with pre-existing health conditions.

• Psychological Risks: 4C-I can induce anxiety, paranoia, or emotional overwhelm, especially in unprepared users or those with underlying mental health issues. Proper set, setting, and dosage reduce these risks.

• No Known Organ Toxicity: There is no indication that 4C-I causes liver or kidney damage when used at moderate doses, but data is limited, and long-term safety remains unknown.

• Contraindications: People with heart disease, epilepsy, bipolar disorder, or schizophrenia should avoid all psychedelics, including 4C-I, due to increased risk of adverse effects.

• Not for Repeated Use: Due to rapid tolerance and unknown long-term effects, frequent use is discouraged. Responsible intervals between sessions are advised.

4C-I primarily interacts with the brain’s serotonin system, which regulates mood, perception, and cognition. Like many classical psychedelics, it binds to serotonin receptors to disrupt ordinary sensory processing and expand states of consciousness. This interaction is at the core of its hallucinogenic and introspective effects.

• 5-HT2A Agonist Activity: 4C-I has a high affinity for 5-HT2A receptors, which play a central role in visual hallucinations, altered thinking, and synesthesia during psychedelic experiences.

• 5-HT2C and 5-HT1A Involvement: Secondary binding at these receptors contributes to mood regulation, emotional sensitivity, and the calming afterglow reported by users.

• Cortical Overactivation: Psychedelics like 4C-I increase activity in the brain’s visual cortex and decrease filtering of sensory input, leading to enhanced perception and complex visual distortions.

• Default Mode Network Disruption: 4C-I may reduce activity in the brain’s default mode network (DMN), which is associated with ego identity and self-referential thinking. This results in feelings of unity or ego softening.

• Increased Neuroplasticity (Theoretical): Some animal studies suggest phenethylamines may promote neural plasticity or enhanced brain connectivity, though no conclusive data exists for 4C-I.

• Minimal Dopamine Activity: 4C-I is not strongly dopaminergic, which is why it doesn’t produce euphoria or compulsive redosing behavior typical of stimulants or addictive substances.

• Temporal Disruption: The compound affects the brain’s sense of time, leading to temporal dilation (time feeling slower), a common characteristic of psychedelic experiences.

Like all psychedelics, 4C-I can produce side effects, both physical and psychological. These effects are typically temporary but can vary in intensity based on dosage, personal sensitivity, and the environment in which the substance is taken. Knowing what to expect helps users prepare for and manage side effects more effectively.

• Nausea or Gastrointestinal Discomfort: This is common during the come-up phase, especially when taken on a full stomach. It typically resolves after the peak is reached.

• Pupil Dilation and Light Sensitivity: Like many serotonergic compounds, 4C-I causes noticeable pupil dilation, which can lead to increased sensitivity to light and slight visual strain.

• Increased Heart Rate and Blood Pressure: Mild cardiovascular stimulation is common, though it’s usually well-tolerated by healthy individuals. Users with heart conditions should avoid use.

• Insomnia or Sleep Disturbance: Due to its stimulating and long-lasting effects, 4C-I may make it difficult to sleep for several hours post-experience.

• Anxiety or Paranoia: This is more likely at high doses or in chaotic environments. A calm setting and trusted companion reduce this risk significantly.

• Cognitive Confusion: Some users experience temporary confusion, difficulty forming sentences, or racing thoughts. These effects usually pass during the afterglow phase.

• Post-Trip Fatigue or Emotional Drain: After intense emotional experiences, users may feel tired, drained, or mentally raw. Proper hydration, nutrition, and rest aid in recovery.

Although 4C-I has not been formally studied in clinical therapeutic settings, anecdotal reports suggest it may have value in promoting emotional clarity, trauma processing, and psychological insight. Its gentle visuals and introspective nature make it a potential tool for personal growth, provided it’s used responsibly and with the right intention.

• Emotional Insight and Release: Users report confronting suppressed memories, unresolved emotions, and existential questions. This can support self-awareness and psychological breakthroughs.

• Non-Verbal Processing: The altered state allows individuals to process emotional material without needing to articulate it, which can be helpful for trauma survivors or those with communication barriers.

• Ego Softening Without Full Dissolution: 4C-I can reduce rigid thinking and defensive patterns, allowing users to examine their identity from a new angle while still maintaining grounded awareness.

• Creative Problem Solving: Some users use 4C-I for reflective brainstorming or artistic exploration, experiencing fluid ideation and new perspectives.

• Potential for Integration Work: The extended afterglow may enhance the effectiveness of talk therapy or journaling in the days following the experience.

• Not a Clinically Approved Treatment: Despite its promise, 4C-I is not approved for psychotherapy or medical use. Self-guided sessions carry risks and should not replace professional treatment.

• Requires Ideal Setting and Support: For any therapeutic use, a quiet, safe space and access to integration support (e.g., therapist, guide, or support group) are essential.